Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America

Autores
Alonso Padilla, Julio; Cortés Serra, Nuria; Pinazo, María Jesús; Bottazzi, María Elena; Abril, Marcelo; Barreira, Fabiana; Sosa-Estani, Sergio Alejandro; Hotez, Peter Jay; Gascón, Joaquim
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage. Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. Although there has been progress improving the research and development (R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries. Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to diagnosis and treatment.
Fil: Alonso Padilla, Julio. Universidad de Barcelona; España
Fil: Cortés Serra, Nuria. Universidad de Barcelona; España
Fil: Pinazo, María Jesús. Universidad de Barcelona; España
Fil: Bottazzi, María Elena. Texas Children's Hospital Houston; Estados Unidos. Baylor University; Estados Unidos. Baylor College Of Medicine; Estados Unidos
Fil: Abril, Marcelo. Fundación Mundo Sano; Argentina
Fil: Barreira, Fabiana. No especifíca;
Fil: Sosa-Estani, Sergio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Hotez, Peter Jay. Texas Children's Hospital Houston; Estados Unidos. Baylor College Of Medicine; Estados Unidos. Baylor University; Estados Unidos
Fil: Gascón, Joaquim. Universidad de Barcelona; España
Materia
CHAGAS DISEASE
COMPREHENSIVE CARE
DIAGNOSIS
PHARMACOVIGILANCE
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/148235
Acceder
id CONICETDig_ff317a1bbc8756c7e608360b4336bc75
oai_identifier_str oai:ri.conicet.gov.ar:11336/148235
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin AmericaAlonso Padilla, JulioCortés Serra, NuriaPinazo, María JesúsBottazzi, María ElenaAbril, MarceloBarreira, FabianaSosa-Estani, Sergio AlejandroHotez, Peter JayGascón, JoaquimCHAGAS DISEASECOMPREHENSIVE CAREDIAGNOSISPHARMACOVIGILANCETREATMENThttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage. Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. Although there has been progress improving the research and development (R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries. Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to diagnosis and treatment.Fil: Alonso Padilla, Julio. Universidad de Barcelona; EspañaFil: Cortés Serra, Nuria. Universidad de Barcelona; EspañaFil: Pinazo, María Jesús. Universidad de Barcelona; EspañaFil: Bottazzi, María Elena. Texas Children's Hospital Houston; Estados Unidos. Baylor University; Estados Unidos. Baylor College Of Medicine; Estados UnidosFil: Abril, Marcelo. Fundación Mundo Sano; ArgentinaFil: Barreira, Fabiana. No especifíca;Fil: Sosa-Estani, Sergio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Hotez, Peter Jay. Texas Children's Hospital Houston; Estados Unidos. Baylor College Of Medicine; Estados Unidos. Baylor University; Estados UnidosFil: Gascón, Joaquim. Universidad de Barcelona; EspañaExpert Reviews2019-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/148235Alonso Padilla, Julio; Cortés Serra, Nuria; Pinazo, María Jesús; Bottazzi, María Elena; Abril, Marcelo; et al.; Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America; Expert Reviews; Expert Review of Anti-infective Therapy; 17; 3; 2-2019; 145-1571478-7210CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1080/14787210.2019.1577731info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14787210.2019.1577731info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:28:15Zoai:ri.conicet.gov.ar:11336/148235instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:28:16.177CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
title Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
spellingShingle Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
Alonso Padilla, Julio
CHAGAS DISEASE
COMPREHENSIVE CARE
DIAGNOSIS
PHARMACOVIGILANCE
TREATMENT
title_short Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
title_full Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
title_fullStr Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
title_full_unstemmed Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
title_sort Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America
dc.creator.none.fl_str_mv Alonso Padilla, Julio
Cortés Serra, Nuria
Pinazo, María Jesús
Bottazzi, María Elena
Abril, Marcelo
Barreira, Fabiana
Sosa-Estani, Sergio Alejandro
Hotez, Peter Jay
Gascón, Joaquim
author Alonso Padilla, Julio
author_facet Alonso Padilla, Julio
Cortés Serra, Nuria
Pinazo, María Jesús
Bottazzi, María Elena
Abril, Marcelo
Barreira, Fabiana
Sosa-Estani, Sergio Alejandro
Hotez, Peter Jay
Gascón, Joaquim
author_role author
author2 Cortés Serra, Nuria
Pinazo, María Jesús
Bottazzi, María Elena
Abril, Marcelo
Barreira, Fabiana
Sosa-Estani, Sergio Alejandro
Hotez, Peter Jay
Gascón, Joaquim
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CHAGAS DISEASE
COMPREHENSIVE CARE
DIAGNOSIS
PHARMACOVIGILANCE
TREATMENT
topic CHAGAS DISEASE
COMPREHENSIVE CARE
DIAGNOSIS
PHARMACOVIGILANCE
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage. Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. Although there has been progress improving the research and development (R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries. Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to diagnosis and treatment.
Fil: Alonso Padilla, Julio. Universidad de Barcelona; España
Fil: Cortés Serra, Nuria. Universidad de Barcelona; España
Fil: Pinazo, María Jesús. Universidad de Barcelona; España
Fil: Bottazzi, María Elena. Texas Children's Hospital Houston; Estados Unidos. Baylor University; Estados Unidos. Baylor College Of Medicine; Estados Unidos
Fil: Abril, Marcelo. Fundación Mundo Sano; Argentina
Fil: Barreira, Fabiana. No especifíca;
Fil: Sosa-Estani, Sergio Alejandro. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Hotez, Peter Jay. Texas Children's Hospital Houston; Estados Unidos. Baylor College Of Medicine; Estados Unidos. Baylor University; Estados Unidos
Fil: Gascón, Joaquim. Universidad de Barcelona; España
description Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage. Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing anti-T. cruzi drug clinical trials. Although there has been progress improving the research and development (R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries. Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to diagnosis and treatment.
publishDate 2019
dc.date.none.fl_str_mv 2019-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/148235
Alonso Padilla, Julio; Cortés Serra, Nuria; Pinazo, María Jesús; Bottazzi, María Elena; Abril, Marcelo; et al.; Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America; Expert Reviews; Expert Review of Anti-infective Therapy; 17; 3; 2-2019; 145-157
1478-7210
CONICET Digital
CONICET
url http://hdl.handle.net/11336/148235
identifier_str_mv Alonso Padilla, Julio; Cortés Serra, Nuria; Pinazo, María Jesús; Bottazzi, María Elena; Abril, Marcelo; et al.; Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America; Expert Reviews; Expert Review of Anti-infective Therapy; 17; 3; 2-2019; 145-157
1478-7210
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1080/14787210.2019.1577731
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14787210.2019.1577731
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Expert Reviews
publisher.none.fl_str_mv Expert Reviews
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083423243862016
score 13.22299

Publicaciones similares